Kind Patches Lawsuit: Dopamine and GLP-1 Patches Challenged in Court
Questions about this case?
AI Legal Assistant · free · answers in seconds · general information, not legal advice
The Kind Patches lawsuit in the news is Maggi et al. v. Kind Patches Limited, filed July 29, 2026 in federal court in New York. It alleges the “Dopamine Patches” — now sold as Mood+ — contain no dopamine. A separate 2025 suit targets the GLP-1 patches. As of October 2026, neither case has a settlement, a fund or a claim form.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
What the Lawsuits Say
Kind Patches Limited is a UK company, registered in England and Wales with its office in Berkhamsted, that sells adhesive “wellness” patches online and in stores. Two U.S. class actions attack two different products.
Dopamine (Mood+) patches. The complaint says the front label promises “Mental Wellness” and “Support[] Dopamine and Serotonin Production,” while the ingredient list shows mucuna pruriens extract (12mg), 5-HTP (5mg), lion’s mane extract (4.5mg) and rhodiola extract (3.5mg) — and no dopamine. The lawsuit alleges the herbal blend cannot deliver the advertised mood benefits through the skin and calls the marketing “nothing but a sham.” It also alleges Kind admitted in fine print on its website that the patches do not contain dopamine.
GLP-1 patches. The earlier suit alleges Kind marketed its GLP-1 patches as a “Natural Version of Ozempic” although they contain berberine, pomegranate and cinnamon extracts, L-glutamine and B vitamins, not a GLP-1 drug. The product has since been renamed “Berberine Patches (Formerly GLP-1).”
These are allegations. We found no U.S. court ruling on whether they are true.
Case Details
Dopamine / Mood+ case: Maggi et al. v. Kind Patches Limited, No. 1:26-cv-01466, U.S. District Court for the Northern District of New York, filed July 29, 2026 by four buyers — two from New York, two from California. Claims: New York General Business Law, California’s Unfair Competition Law, False Advertising Law and Consumers Legal Remedies Act, and unjust enrichment. Counsel: KalielGold PLLC.
GLP-1 case: Alaimo v. Kind Patches Limited, No. 1:25-cv-06092, U.S. District Court for the Eastern District of New York, filed October 31, 2025. Claims under New York General Business Law. Counsel: Janove PLLC and Zimmerman Reed LLP.
UK regulator: On February 4, 2026 the UK Advertising Standards Authority ruled that four Kind Facebook ads, including one for the Dopamine patch, were misleading and unsubstantiated. That is an advertising ruling in Britain, not a U.S. court finding, and it pays nothing.
Status: Two Open Cases, No Settlement
Follow this case
There's no claim deadline yet. We'll email you if a settlement opens a claim period.
Who Would Be Included
The dopamine complaint proposes a nationwide class of everyone in the United States who bought Kind Dopamine Patches within the statute of limitations, plus separate New York and California classes. The GLP-1 complaint proposes a nationwide class of U.S. buyers of the GLP-1 patches.
Nothing needs to be done to be included. Commenting “add me” on a news site does not sign anyone up for anything. What helps later: keep order emails, receipts or Amazon order history. The complaint notes receipts often still say “Dopamine Patches” even after the Mood+ rename.
What Buyers Could Get
Kind Patches Lawsuit Timeline
- 1
June–July 2025 — Facebook Ads Run in the UK
Kind runs paid Facebook ads for its NAD+ and Dopamine patches, among others. They later become the subject of a regulator complaint.
- 2
October 31, 2025 — GLP-1 Patch Suit Filed
Alaimo v. Kind Patches Limited (1:25-cv-06092) is filed in the Eastern District of New York over the GLP-1 patches.
- 3
February 4, 2026 — UK Regulator Rules Ads Misleading
The Advertising Standards Authority finds the claims unsubstantiated and says the ads must not appear again in that form.
- 4
July 29, 2026 — Dopamine Patch Suit Filed
Four buyers file Maggi et al. v. Kind Patches Limited (1:26-cv-01466) in the Northern District of New York.
- 5
September 2026 — The Case Hits the News
Consumer-news sites report the dopamine complaint on September 4, 2026, driving the current search interest.
- 6
As of October 2026 — No Settlement
We found no report of a settlement, fund, claim form or deadline in either case.
Three Things to Watch For
A popular product, a viral lawsuit and no claim form is the gap scammers like to fill:
“Claim your Kind Patches refund” sites
There is no settlement, so there is no official claim site. A page asking for card details or a Social Security number to “release your refund” is not connected to either case.
“Add me” comment replies
Many readers post “add me” under news articles. Replies or DMs that follow up asking for payment or ID to join the class are not from the court or plaintiffs’ counsel. Joining costs nothing.
Fake Kind Patches discount offers
Messages that pair the lawsuit with a “compensation coupon” or a free replacement pack usually lead to look-alike stores. Any real notice will come from a court-appointed administrator.
Kind Patches Lawsuit — Questions People Ask
What is the Kind Patches lawsuit about?
Two federal class actions in New York. The newer one, filed July 29, 2026, alleges the Dopamine (now Mood+) patches contain no dopamine and do not work as advertised. The older one, filed October 31, 2025, alleges the GLP-1 patches were falsely compared to Ozempic.
Is there a Kind Patches settlement or claim form?
No. As of October 2026 no settlement has been reported in either case. There is no fund, no administrator, no claim form and no deadline.
I bought Kind dopamine patches. Am I part of the case?
If you bought them in the U.S. within the statute of limitations, you fall within the proposed nationwide class. A class only exists once a judge certifies it or approves a settlement; you would then be notified and could file a claim or opt out.
Do Kind dopamine patches contain dopamine?
According to the complaint, the label lists mucuna pruriens, 5-HTP, lion’s mane and rhodiola extracts — no dopamine. The lawsuit alleges Kind acknowledged this in fine print on its website. A court has not ruled on whether the marketing was misleading.
Is this the same as the GLP-1 or Ozempic lawsuits?
No. The GLP-1 drug lawsuits are injury claims against makers of prescription drugs like Ozempic. The Kind case is a consumer false-advertising suit over a supplement patch that, the complaint says, contains no GLP-1 drug.
What did the UK regulator decide?
On February 4, 2026 the Advertising Standards Authority ruled four Kind Facebook ads misleading, finding the cited trials mostly gave ingredients orally and in larger amounts than the patches contain. The ASA lists further upheld rulings against Kind dated July 15 and September 2, 2026.
Should I keep my receipts?
Yes. Save order confirmations, card statements or retailer order history. Settlements in product cases often pay more to buyers with proof of purchase. See which settlements pay without proof.
Do I need a lawyer or to sign up anywhere?
No sign-up is needed to be included in a class action. Posting “add me” online does nothing. If you have a separate injury or a large loss, talk to a licensed attorney about your own options.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.